{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetes+Mellitus%2C+Type+II&page=44",
    "query": {
      "condition": "Diabetes Mellitus, Type II",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 3676,
    "total_pages": 368,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetes+Mellitus%2C+Type+II&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetes+Mellitus%2C+Type+II&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T13:55:25.480Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04657003",
      "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 938,
      "start_date": "2021-03-29",
      "completion_date": "2023-04-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04657003"
    },
    {
      "nct_id": "NCT00603291",
      "title": "BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Lorcaserin 10 mg once daily (QD)",
          "type": "DRUG"
        },
        {
          "name": "Lorcaserin 10 mg twice a day (BID)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 604,
      "start_date": "2007-12",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603291"
    },
    {
      "nct_id": "NCT00201110",
      "title": "Problem Solving and Cardiovascular Disease Risk Management in Diabetic Blacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Heart Diseases",
        "Diabetes Mellitus, Type 2",
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "Problem Solving Skills",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 139,
      "start_date": "2004-07",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2013-03-20",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201110"
    },
    {
      "nct_id": "NCT00099723",
      "title": "The Effect of a Probiotic on Hepatic Steatosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "VSL#3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VSL Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "45 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-10",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2010-02-11",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099723"
    },
    {
      "nct_id": "NCT01580813",
      "title": "Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Acipimox",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "30 Years to 60 Years"
      },
      "enrollment_count": 13,
      "start_date": "2011-06",
      "completion_date": "2015-06-05",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01580813"
    },
    {
      "nct_id": "NCT01142297",
      "title": "Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Partially Edentulous Mandible",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "dental implant and modified dental implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2008-07",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-01-03",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01142297"
    },
    {
      "nct_id": "NCT02009488",
      "title": "Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 59,
      "start_date": "2014-09-08",
      "completion_date": "2017-01-03",
      "has_results": false,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 2,
      "location_summary": "San Diego, La Jolla, California • Gainesville, Florida",
      "locations": [
        {
          "city": "San Diego, La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02009488"
    },
    {
      "nct_id": "NCT01339520",
      "title": "Diabetes Scorecard Educational Intervention Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Scorecard",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "George Washington University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2008-11",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2017-08-11",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01339520"
    },
    {
      "nct_id": "NCT00241423",
      "title": "Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-10",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2015-02-23",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • San Antonio, Texas",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241423"
    },
    {
      "nct_id": "NCT05925920",
      "title": "Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "ENT-03",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Metabolics Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 49,
      "start_date": "2023-06-13",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-16T13:55:25.480Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05925920"
    }
  ]
}